Fumi Ishikawa

Fumi Ishikawa

Auto-generated profile, based on publicly available information

Fumi Ishikawa

Allergy Center, National Center for Child Health and Development Tokyo Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
KNKoji Nishimura
Koji Nishimura
KYKiwako Yamamoto
Kiwako Yamamoto
MSMiori Sato
Miori Sato
KTKenji Toyokuni
Kenji Toyokuni
HOHiroya Ogita
Hiroya Ogita
YOYukihiro Ohya
Yukihiro Ohya
The oral food challenge test (OFC) is the gold standard for evaluating the remission of food protein-induced enterocolitis syndrome (FPIES). Few acute FPIES remissions confirmed by OFC were reported. This study aimed to examine the OFC for Japanese children with acute FPIES to evaluate its remission. A retrospective cohort study was performed on children with acute FPIES with remission evaluation by OFC based on one food challenge dose (1/50, 1/10, 1/2, and full dose per day). Acute FPIES remission was observed in 65.2% of patients (15/23 patients). Vomiting episodes occurred with 1/50 full doses on the first day among 75% of positive patients. The median duration between the onset and OFC was 14 months (IQR, 8–24 months). Soy was the most common causative food, followed by egg yolk, milk, and wheat. All patients could receive OFC safely without intensive care unit care, based on the FPIES OFC protocol. The remission rate of acute FPIES was high. However, vomiting episodes commonly occurred with 1/50 full doses on the first day. This study suggested that our OFC protocol for acute FPIES was safe and feasible, but it might be safer for some patients to start at a minimal loading dose.

27 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
HYHIROKI YASUDO
HIROKI YASUDO
KYKiwako Yamamoto
Kiwako Yamamoto
LYLimin Yang
Limin Yang
MSMayako Saito-Abe
Mayako Saito-Abe
MSMiori Sato
Miori Sato
YOYukihiro Ohya
Yukihiro Ohya
The association between pollen food allergy syndrome (PFAS) and allergic march remains unclear. In this prospective cohort study of the general population in Tokyo (T-Child Study), we found that sensitization to Cry j 1 and Fel d 1 at ages 5 and 9 years was associated with an increased risk of PFAS at 13 years old (at 5 years, Cry j 1: adjusted odds ratio aOR, 2.74; 95% confidence interval CI, 1.53–4.91; Fel d 1: aOR, 2.61; 95% CI, 1.31–5.19; at 9 years, Cry j 1: adjusted odds ratio aOR, 4.28; 95% confidence interval CI, 1.98–9.25; Fel d 1: aOR, 2.40; 95% CI, 1.33–4.32). In particular, sensitization to Bet v 1 at ages 5 and 9 years was associated with a strong risk of PFAS at the age of 13 years (at 5 years: aOR, 10.6; 95% CI, 2.64–42.5; at 9 years: aOR, 9.1; 95% CI, 4.71–17.6). PFAS risk by age 13 years was increased by any allergic symptom at 5 or 9 years, a combination of wheezing, eczema, and rhinitis, and Bet v 1 sensitization. Our findings suggest that PFAS may be associated with allergic march.

21 February 2026 in Allergy
Verified
Journal Article
Closed access
PDF file
KYKiwako Yamamoto
Kiwako Yamamoto
MSMayako Saito-Abe
Mayako Saito-Abe
MSMiori Sato
Miori Sato
FIFumi Ishikawa
Fumi Ishikawa
KTKenji Toyokuni
Kenji Toyokuni
YOYukihiro Ohya
Yukihiro Ohya

24 July 2025 in Journal of Allergy and Clinical Immunology: Global
Verified
Journal Article
Open access
FIFumi Ishikawa
Fumi Ishikawa
YMYumiko Miyaji
Yumiko Miyaji
KYKiwako Yamamoto-Hanada
Kiwako Yamamoto-Hanada
MSMami Shimada
Mami Shimada
TKTomoyuki Kiguchi
Tomoyuki Kiguchi
YOYukihiro Ohya
Yukihiro Ohya
Adverse events could be a barrier to implementing oral immunotherapy (OIT) in children with hen's egg (HE) allergy, highlighting the need for safer OIT methods. To determine the safety and efficacy of a new OIT method in a single-center, phase II, double-blind, parallel-group, randomized controlled trial. Children aged 1 to 18 years with HE allergy whose cumulative tolerated dose (CTD) range was greater than or equal to 0.1 g to less than 10 g in the oral food challenge test were randomly assigned to the experimental therapy (ET) group with a very low starting dose or to the standard therapy (ST) group with a fixed-quantity maintenance dose for OIT. The primary outcome was safety, measured by days on OIT before the first IgE-mediated immediate-type reaction. The OIT efficacy, the change in CTD, was to be evaluated. Among 20 participants at registration, 12 (60%) and 8 (40%) participants were allocated to the ET and ST groups, respectively. Although the study was prematurely terminated because of difficulty in the safe supply of immunotherapy food, the number of days before the first IgE-mediated immediate-type reaction was more in the ET group than in the ST group (P = .033, log-rank test). The adverse event rate was also lower in the ET group; all of these might improve adherence to the treatment method. The change in CTD could not be compared between the 2 groups. OIT with a very low starting dose might be a safer approach with a low treatment burden for children with HE allergies.

16 September 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
CJChisato Jimbo
Chisato Jimbo
SHSayaka Hamaguchi
Sayaka Hamaguchi
KTKenji Toyokuni
Kenji Toyokuni
MSMiori Sato
Miori Sato
AKAi Kishino
Ai Kishino
KYKiwako Yamamoto
Kiwako Yamamoto

23 July 2024 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
SHSayaka Hamaguchi
Sayaka Hamaguchi
DHDaisuke Harama
Daisuke Harama
MSMayako Saito-Abe
Mayako Saito-Abe
FIFumi Ishikawa
Fumi Ishikawa
MSMiori Sato
Miori Sato
KYKiwako Yamamoto
Kiwako Yamamoto